Abstract
Biaryl anthranilides are reported as potent and selective full agonists for the high affinity niacin receptor GPR109A. The SAR presented outlines approaches to reduce serum shift and both CYPCYP2C8 and CYP2C9 liabilities, while improving PK and maintaining excellent receptor activity. Compound 2i exhibited good in vivo antilipolytic efficacy while providing a significantly improved therapeutic index over vasodilation (flushing) with respect to niacin in the mouse model.
MeSH Terms
Amides/chemical synthesis,pharmacokinetics,pharmacology
Animals
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors
Binding, Competitive
CHO Cells
Cricetinae
Cricetulus
Cytochrome P-450 CYP2C8
Cytochrome P-450 CYP2C9
Humans
In Vitro Techniques
Mice
Microsomes, Liver/metabolism
Radioligand Assay
Receptors, G-Protein-Coupled/agonists
Receptors, Nicotinic
Structure-Activity Relationship
ortho-Aminobenzoates/chemical synthesis,pharmacokinetics,pharmacology
Chemicals
Amides
HCAR2 protein, human
HCAR3 protein, human
Receptors, G-Protein-Coupled
Receptors, Nicotinic
ortho-Aminobenzoates
CYP2C9 protein, human
Cytochrome P-450 CYP2C9
Aryl Hydrocarbon Hydroxylases
CYP2C8 protein, human
Cytochrome P-450 CYP2C8
Authors & Affiliations
23 authors, click to expand affiliations / ORCID
Shen Hong C
Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey 07065-0900, USA. hong_shen@merck.com
Ding Fa-Xiang
Luell Silvi
Forrest Michael J
Carballo-Jane Ester
Wu Kenneth K
Wu Tsuei-Ju
Cheng Kang
Wilsie Larissa C
Krsmanovic Mihajlo L
Taggart Andrew K
Ren Ning
Cai Tian-Quan
Deng Qiaolin
Chen Qing
Wang Junying
Wolff Michael S
Tong Xinchun
Holt Tom G
Waters M Gerard
Hammond Milton L
Tata James R
Colletti Steven L